{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T02:59:26Z","timestamp":1787885966753,"version":"build-2784847793"},"reference-count":151,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abbot Laboratories","award":["RRTI8626"],"award-info":[{"award-number":["RRTI8626"]}]},{"name":"National Research Council (CNPq)","award":["RRTI8626"],"award-info":[{"award-number":["RRTI8626"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Depression is one of the leading causes of disability worldwide. Among pharmacological treatments, fluvoxamine\u2014an early SSRI with a distinct pharmacological profile\u2014has been recently reappraised for its broader clinical relevance. Objective: To assess the efficacy of fluvoxamine in the treatment of depression compared to placebo and other antidepressants through a comprehensive overview of systematic reviews and meta-analyses. Methods: A systematic search was conducted in MEDLINE and the Cochrane Central Register of Controlled Trials, including systematic reviews and meta-analyses of randomized controlled trials evaluating fluvoxamine\u2019s efficacy. Reviews were eligible if they included adults diagnosed with depressive disorders based on the DSM or ICD criteria. Reviews focusing on other psychiatric disorders, comorbidities, tolerability, or economic evaluations were excluded. Data extraction included effect size measures and methodological quality assessments using the AMSTAR-2 tool. Results were synthesized by comparing fluvoxamine to placebo, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants. Results: A total of 74 reviews were identified, of which 14 systematic reviews met the inclusion criteria after screening and full-text analysis. These reviews, published between 1994 and 2021, predominantly involved nine pairwise meta-analyses and five network meta-analyses, comparing fluvoxamine with placebo and various antidepressants. Fluvoxamine demonstrated consistent superiority over placebo in achieving treatment response and remission outcomes. Comparisons with imipramine, clomipramine, amitriptyline, dothiepin, paroxetine, fluoxetine, citalopram, mianserin, nortriptyline, and moclobemide generally revealed no significant differences in efficacy. However, some reviews indicated that venlafaxine and mirtazapine were superior to fluvoxamine in certain outcomes, while fluvoxamine demonstrated greater efficacy than desipramine in one review. Sertraline and milnacipran showed mixed or review-quality-dependent results, with one low-quality review favoring milnacipran. Most reviews assessed outcomes over a median follow-up of six weeks using standardized depression rating scales. Conclusions: Fluvoxamine is a robust and effective antidepressant, demonstrating consistent efficacy comparable to other antidepressants and superior to placebo. While no single antidepressant was universally superior, fluvoxamine\u2019s unique pharmacological profile and favourable safety characteristics support its clinical utility. Further research is needed to explore its role in personalized treatment strategies and emerging therapeutic contexts, such as comorbid anxiety and post-traumatic stress disorder.<\/jats:p>","DOI":"10.3390\/ph18050711","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:59:26Z","timestamp":1747108766000},"page":"711","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Overview of the Systematic Reviews About the Efficacy of Fluvoxamine on Depression"],"prefix":"10.3390","volume":"18","author":[{"given":"Luiz Henrique Junqueira","family":"Dieckmann","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, SP, Brazil"},{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04017-030, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4320-2772","authenticated-orcid":false,"given":"Michel","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, SP, Brazil"},{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04017-030, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-1695","authenticated-orcid":false,"given":"Thiago","family":"Wendt Viola","sequence":"additional","affiliation":[{"name":"School of Medicine, Brain Institute of Rio Grande do Sul, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciele","family":"Franco Scarante","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0155-2670","authenticated-orcid":false,"given":"Naielly","family":"Rodrigues da Silva","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brazilian Clinical Research Institute, S\u00e3o Paulo 01404-000, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5403-0112","authenticated-orcid":false,"given":"Jair de Jesus","family":"Mari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04017-030, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"GBD 2019 Mental Disorders Collaborators (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry, 9, 137\u2013150.","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1192\/bjp.bp.116.188078","article-title":"Undertreatment of people with major depressive disorder in 21 countries","volume":"210","author":"Thornicroft","year":"2017","journal-title":"Br. J. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjc.12333","article-title":"Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis","volume":"61","author":"Shorey","year":"2022","journal-title":"Br. J. Clin. Psychol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1037\/bul0000102","article-title":"Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms","volume":"143","author":"Salk","year":"2017","journal-title":"Psychol. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapsychiatry.2018.4500","article-title":"Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis","volume":"76","author":"Gobbi","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12991-021-00375-x","article-title":"Prevalence and determinants of depression among old age: A systematic review and meta-analysis","volume":"20","author":"Zenebe","year":"2021","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41398-023-02464-9","article-title":"Biological factors influencing depression in later life: Role of aging processes and treatment implications","volume":"13","author":"Szymkowicz","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41380-019-0385-5","article-title":"Data-driven biological subtypes of depression: Systematic review of biological approaches to depression subtyping","volume":"24","author":"Beijers","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1569","DOI":"10.1002\/mpr.1569","article-title":"Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder","volume":"27","author":"Musil","year":"2018","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mp.2012.144","article-title":"Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression","volume":"18","author":"Lamers","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jpsychires.2024.05.002","article-title":"Characterization of depression subtypes and their relationships to stressor profiles among middle-aged and older adults: An analysis of the canadian longitudinal study on aging (CLSA)","volume":"175","author":"Spiegler","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41591-024-03057-9","article-title":"Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety","volume":"30","author":"Tozzi","year":"2024","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0038550","article-title":"A brief history of the development of antidepressant drugs: From monoamines to glutamate","volume":"23","author":"Hillhouse","year":"2015","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_15","unstructured":"Della Sala, S. (2022). Antidepressant Drugs: Mechanisms of Action and Side Effects. Encyclopedia of Behavioral Neuroscience, Elsevier. [2nd ed.]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01252962","article-title":"Fluvoxamine-a new serotonin re-uptake inhibitor: First clinical and psychometric experiences in depressed patients","volume":"41","author":"Saletu","year":"1977","journal-title":"J. Neural Transm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"349S","DOI":"10.1111\/j.1365-2125.1983.tb02125.x","article-title":"Review of the animal pharmacology and pharmacokinetics of fluvoxamine","volume":"15","author":"Claassen","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_18","first-page":"10","article-title":"Pharmacology of serotonin uptake inhibitors: Focus on fluvoxamine","volume":"16","author":"Hrdina","year":"1991","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejphar.2017.05.035","article-title":"Psychopharmacology of combined activation of the serotonin","volume":"809","author":"Ago","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","article-title":"Cognition and depression: The effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered","volume":"25","author":"Hindmarch","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: A positron emission tomography study using [11C]SA4503","volume":"62","author":"Ishikawa","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ren, P., Wang, J., Li, N., Li, G., Ma, H., Zhao, Y., and Li, Y. (2022). Sigma-1 Receptors in Depression: Mechanism and Therapeutic Development. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.925879"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105390","DOI":"10.1016\/j.neuint.2022.105390","article-title":"Sigma-1 receptor: A potential target for the development of antidepressants","volume":"159","author":"Wang","year":"2022","journal-title":"Neurochem. Int."},{"key":"ref_24","first-page":"25","article-title":"Pharmacogenetic Aspects of COVID-19 Management and Post-COVID-19 Depression Treatment with Fluvoxamine","volume":"34","author":"Dobrodeeva","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/wps.20983","article-title":"Repurposing fluvoxamine, and other psychiatric medications, for COVID-19 and other conditions","volume":"21","author":"Lenze","year":"2022","journal-title":"World Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","article-title":"Mechanisms of action of fluvoxamine for COVID-19: A historical review","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: An international consensus statement","volume":"267","author":"Arango","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"em513","DOI":"10.29333\/ejgm\/13295","article-title":"Potential strategies to optimize the efficacy of antidepressants: Beyond the monoamine theory","volume":"20","author":"Gammoh","year":"2023","journal-title":"Electron. J. Gen. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Haddad, M., Dieckmann, L.H.J., Viola, T.W., de Ara\u00fajo, M.R., da Silva, N.R., and Mari, J.J. (2025). The Efficacy of Fluvoxamine in Anxiety Disorders and Obsessive-Compulsive Disorder: An Overview of Systematic Reviews and Meta-Analyses. Pharmaceuticals, 18.","DOI":"10.3390\/ph18030353"},{"key":"ref_32","unstructured":"(2025, April 25). European Medicines Agency Floxyfral Registration. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/summary-information-referral-opinion-following-arbitration-pursuant-article-30-council-directive-200183ec-floxyfral-and-associated-names-international-non-proprietary-name-inn-fluvoxamine-background_en.pdf."},{"key":"ref_33","unstructured":"(2025, April 25). FDA Label\u2014Fluvoxamine (Luvox\u00ae) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022235lbl.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/neu.2020.6","article-title":"Pharmacological treatments for social anxiety disorder in adults: A systematic review and network meta-analysis","volume":"32","author":"Williams","year":"2020","journal-title":"Acta Neuropsychiatr."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Zhao, G., Pan, Y., Zhang, Y., and Ni, Y. (2024). The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0300512"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","article-title":"Overview of the pharmacokinetics of fluvoxamine","volume":"29","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-199427030-00002","article-title":"Clinical pharmacokinetics of fluvoxamine","volume":"27","author":"Perucca","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Burhanuddin, K., and Badhan, R. (2022). Optimising Fluvoxamine Maternal\/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study. Metabolites, 12.","DOI":"10.3390\/metabo12121281"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/0269881108089876","article-title":"Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: Meta-analysis","volume":"23","author":"Omori","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"ref_40","first-page":"CD006114","article-title":"Fluvoxamine versus other anti-depressive agents for depression","volume":"2010","author":"Omori","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/026988119400800407","article-title":"The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants","volume":"8","author":"Anderson","year":"1994","journal-title":"J. Psychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-2007-1014308","article-title":"Efficacy of new generation antidepressants: Meta-analysis of imipramine-controlled studies","volume":"27","author":"Fuger","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00004850-199609004-00006","article-title":"Milnacipran and selective serotonin reuptake inhibitors in major depression","volume":"11","author":"Guelfi","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0165-0327(99)00092-0","article-title":"Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability","volume":"58","author":"Anderson","year":"2000","journal-title":"J. Affect. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2007.06.027","article-title":"Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs","volume":"63","author":"Nemeroff","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"ref_47","first-page":"CD006529","article-title":"Milnacipran versus other antidepressive agents for depression","volume":"2009","author":"Nakagawa","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ramsberg, J., Asseburg, C., and Henriksson, M. (2012). Effectiveness and cost-effectiveness of antidepressants in primary care: A multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042003"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jocn.2020.08.013","article-title":"Application of antidepressants in depression: A systematic review and meta-analysis","volume":"80","author":"Yuan","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jad.2021.01.021","article-title":"Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: A systematic review and network meta-analysis","volume":"282","author":"Suchting","year":"2021","journal-title":"J. Affect. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: A systematic review and network meta-analysis","volume":"28","author":"Kishi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/pcn.13565","article-title":"L-theanine combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial","volume":"77","author":"Nematizadeh","year":"2023","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Farahani, R.H., Ajam, A., and Naeini, A.R. (2023). Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08172-5"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"She, D.P., He, Y., Li, M.Q., Su, L., Ren, D., Huang, X.H., Zhang, Y.H., Hu, H.T., Deng, D.C., and Wu, J.L. (2023). Pharmacokinetics and bioequivalence studies of fluvoxamine maleate tablets in healthy Chinese subjects. Biomed. Chromatogr., 37.","DOI":"10.1002\/bmc.5613"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/npr2.12299","article-title":"Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: A combined post hoc analysis of four clinical trial data","volume":"42","author":"Tsujii","year":"2022","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jpsychires.2022.05.002","article-title":"A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder","volume":"151","author":"Brar","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1097\/00002826-198406001-00286","article-title":"Fluvoxamine: Antidepressant effects confirmed in a placebo-controlled international study","volume":"7","author":"Amin","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/ajp.143.1.88","article-title":"Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor","volume":"143","author":"Brown","year":"1986","journal-title":"Am. J. Psychiatry"},{"key":"ref_61","first-page":"52","article-title":"Use of a standardized documentation system (BLIPS\/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine, and placebo","volume":"22","author":"Cassano","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","article-title":"Fluvoxamine maleate in the treatment of depression: A single-center, double-blind, placebo-controlled comparison with imipramine in outpatients","volume":"16","author":"Claghorn","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_63","first-page":"84","article-title":"A double-blind placebo-controlled study of fluvoxamine and imipramine in depression","volume":"46","author":"Dominguez","year":"1985","journal-title":"J. Clin. Psychiatry"},{"key":"ref_64","first-page":"119","article-title":"Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients","volume":"11","author":"Fabre","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-198907000-00006","article-title":"A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression","volume":"4","author":"Feighner","year":"1989","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"433S","DOI":"10.1111\/j.1365-2125.1983.tb02134.x","article-title":"A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression","volume":"15","author":"Itil","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_67","first-page":"65","article-title":"Treatment of major affective disorder with fluvoxamine","volume":"48","author":"Lapierre","year":"1987","journal-title":"J. Clin. Psychiatry"},{"key":"ref_68","first-page":"68","article-title":"Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: Effects on depression","volume":"25","author":"Lydiard","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"ref_69","first-page":"200","article-title":"A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression","volume":"51","author":"March","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0165-0327(84)90051-X","article-title":"A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients","volume":"7","author":"Norton","year":"1984","journal-title":"J. Affect. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0278-5846(90)90078-U","article-title":"A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression","volume":"14","author":"Roth","year":"1990","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/10401239609147751","article-title":"The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients","volume":"8","author":"Walczak","year":"1996","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00004850-199803000-00001","article-title":"Fluvoxamine prevents recurrence of depression: Results of a long-term, double-blind, placebo-controlled study","volume":"13","author":"Terra","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_74","first-page":"73","article-title":"A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression","volume":"20","author":"Guy","year":"1984","journal-title":"Psychopharmacol. Bull."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0893-133X(00)00232-3","article-title":"Noradrenergic function and clinical outcome in antidepressant pharmacotherapy","volume":"24","author":"Miller","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hup.442","article-title":"Fluvoxamine as effective as clomipramine against symptoms of severe depression: Results from a multicentre, double-blind study","volume":"18","author":"Zohar","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"ref_77","first-page":"427S","article-title":"Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing","volume":"15","author":"Mertens","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_78","first-page":"317","article-title":"Fluvoxamine and clomipramine in depressed hospitalised patients: Results from a randomised, double-blind study","volume":"21","author":"Ottevanger","year":"1995","journal-title":"Encephale"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-0327(95)00012-C","article-title":"Changes in daily life experience associated with clinical improvement in depression","volume":"34","author":"Nicolson","year":"1995","journal-title":"J. Affect. Disord."},{"key":"ref_80","first-page":"89","article-title":"Fluvoxamine versus amitriptyline in depressed hospital out-patients: A multicentre double-blind comparative trial","volume":"2","author":"Harris","year":"1991","journal-title":"Br. J. Clin. Res."},{"key":"ref_81","first-page":"24","article-title":"Comparative efficacy and tolerance of fluvoxamine and amitriptyline in the treatment of moderate and severe depression in mental hospital","volume":"103","author":"Kostiukova","year":"2003","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0011-393X(05)80168-7","article-title":"Comparison of fluvoxamine and amitriptyline in depressed outpatients","volume":"55","author":"Remick","year":"1994","journal-title":"Curr. Ther. Res."},{"key":"ref_83","first-page":"951","article-title":"Clinical evaluation of SME3110 (fluvoxamine maleate) in the treatment of depression and depressive state: A double-blind, comparative study with amitriptyline","volume":"14","author":"Murasaki","year":"1998","journal-title":"Rinsho-Iyaku (J. Clin. Ther. Med.)"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-1241.1988.tb08510.x","article-title":"A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder","volume":"42","author":"Mullin","year":"1988","journal-title":"Br. J. Clin. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1742-1241.1991.tb08868.x","article-title":"A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients","volume":"45","author":"Rahman","year":"1991","journal-title":"Br. J. Clin. Pract."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Tourigny-Rivard, M., Nair, N., and Vincent, P. (1996, January 21\u201325). Fluvoxamine versus desipramine in elderly patients with major depression: A double-blind comparison. Proceedings of the 9th ECNP (European College of Neuropsychopharmacology) Congress, Amsterdam, The Netherlands.","DOI":"10.1016\/0924-977X(96)83081-1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-2005-837769","article-title":"A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression","volume":"38","author":"Otsubo","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/hup.470090502","article-title":"Controlled comparison of paroxetine and fluvoxamine in major depression","volume":"9","author":"Ansseau","year":"1994","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000094727","article-title":"Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients","volume":"53","author":"Kato","year":"2006","journal-title":"Neuropsychobiology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4088\/JCP.v58n0402","article-title":"A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients","volume":"58","author":"Kiev","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/depr.3050030402","article-title":"Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients","volume":"3","author":"Nemeroff","year":"1995","journal-title":"Depression"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.jcp.0000177548.28961.e7","article-title":"Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: A double-blind, randomized trial","volume":"25","author":"Rossini","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00004850-199609000-00002","article-title":"Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: A double-blind, multicentre study. The LUCIFER Group","volume":"11","author":"Haffmans","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hup.490","article-title":"Fluvoxamine versus fluoxetine in major depressive episode: A double-blind randomised comparison","volume":"18","author":"Dalery","year":"2003","journal-title":"Hum. Psychopharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004714-199610000-00005","article-title":"A comparison of fluvoxamine and fluoxetine in the treatment of major depression","volume":"16","author":"Rapaport","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004850-200105000-00003","article-title":"Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine","volume":"16","author":"Clerc","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0924-977X(91)90712-4","article-title":"Interest of a loading dose of milnacipran in endogenous depressive inpatients: Comparison with the standard regimen and with fluvoxamine","volume":"1","author":"Ansseau","year":"1991","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0924-977X(98)80329-5","article-title":"Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression","volume":"8","author":"Hackett","year":"1998","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_99","first-page":"140","article-title":"First, randomized, double-blind comparison of mirtazapine (15\u201345 mg) and fl uvoxamine (50\u2013150 mg) in the treatment of depression","volume":"5","author":"Schoemaker","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_100","first-page":"339","article-title":"Comparison of efficacy and safety of mirtazapine versus fluvoxamine in Japanese and Caucasian patients with major depressive disorder","volume":"13","author":"Murasaki","year":"2010","journal-title":"Rinsho-Seishin-Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1742-1241.1991.tb08869.x","article-title":"The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice","volume":"45","author":"Moon","year":"1991","journal-title":"Br. J. Clin. Pract."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1185\/03007999009111652","article-title":"A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness","volume":"12","author":"Perez","year":"1990","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/mp.2015.53","article-title":"Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression","volume":"21","author":"Hieronymus","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41398-022-02285-2","article-title":"The complex clinical response to selective serotonin reuptake inhibitors in depression: A network perspective","volume":"13","author":"Boschloo","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1368-5031.2006.00865.x","article-title":"Tolerability and safety of fluvoxamine and other antidepressants","volume":"60","author":"Westenberg","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.178.3.234","article-title":"Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors","volume":"178","author":"Thase","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis","volume":"180","author":"Smith","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/YIC.0b013e32834ce13f","article-title":"Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: A meta-analysis of published studies","volume":"27","author":"Hanwella","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jad.2006.04.029","article-title":"Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine","volume":"95","author":"Berlanga","year":"2006","journal-title":"J. Affect. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.31887\/DCNS.2016.18.4\/ncutler","article-title":"Sex differences in the psychopharmacological treatment of depression","volume":"18","author":"Sramek","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1440-1819.2007.01679.x","article-title":"Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients","volume":"61","author":"Naito","year":"2007","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00210-023-02818-6","article-title":"Pharmacological update of mirtazapine: A narrative literature review","volume":"397","author":"Hassanein","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S1092852922000906","article-title":"The prescriber\u2019s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression","volume":"28","author":"Abdelmoemin","year":"2023","journal-title":"CNS Spectr."},{"key":"ref_115","first-page":"35","article-title":"On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression","volume":"53","author":"Parker","year":"2023","journal-title":"Psychopharmacol. Bull."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1570159X17666191001142934","article-title":"An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective","volume":"18","author":"Athira","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41386-020-00789-3","article-title":"Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics","volume":"46","author":"Buch","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, X., Yan, D., Liao, M., Zhang, L., Li, Z., Liu, B., Chen, Y., Zhang, Y., Liu, J., and Li, L. (2023). Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: A prospective follow-up study. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1163754"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1038\/s41467-024-47273-w","article-title":"Immunoregulatory role of the gut microbiota in inflammatory depression","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2021.09.009","article-title":"Rapid response to selective serotonin reuptake inhibitors in post-COVID depression","volume":"54","author":"Mazza","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mp.4000425","article-title":"Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine","volume":"3","author":"Smeraldi","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0278-5846(01)00287-1","article-title":"Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients","volume":"26","author":"Yoshida","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0269881106072192","article-title":"The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine","volume":"21","author":"Yoshida","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.mp.4001494","article-title":"Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response","volume":"9","author":"Kirchheiner","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_126","first-page":"113","article-title":"Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder","volume":"11","author":"Zastrozhin","year":"2018","journal-title":"Pharmacogenomics Pers. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0009-9236(96)90134-4","article-title":"Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity","volume":"60","author":"Carrillo","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbr.2016.05.056","article-title":"Activation of Sigma-1 receptor ameliorates anxiety-like behavior and cognitive impairments in a rat model of post-traumatic stress disorder","volume":"311","author":"Ji","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2478\/s13380-012-0030-0","article-title":"Roles of \u03c31 receptors in the mechanisms of action of CNS drugs","volume":"3","author":"Toyohara","year":"2012","journal-title":"Transl. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neubiorev.2021.10.037","article-title":"Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders","volume":"132","author":"Pytka","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_131","unstructured":"(2025, April 25). Available online: https:\/\/www.crd.york.ac.uk\/prospero\/."},{"key":"ref_132","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2023). Chapter V: Overviews of Reviews. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/sim.8781","article-title":"Evaluation of various estimators for standardized mean difference in meta-analysis","volume":"40","author":"Lin","year":"2021","journal-title":"Stat. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S146114570300364X","article-title":"Fluvoxamine CR in the long-term treatment of social anxiety disorder: The 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial","volume":"6","author":"Stein","year":"2003","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1176\/ajp.155.12.1756","article-title":"Fluvoxamine in the treatment of binge-eating disorder: A multicenter placebo-controlled, double-blind trial","volume":"155","author":"Hudson","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"ref_137","first-page":"815","article-title":"Double-blind comparison of fluvoxamine and imipramine in depressed patients","volume":"4","author":"Amore","year":"1989","journal-title":"Curr. Ther. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-0327(82)90009-X","article-title":"Fluvoxamine and chlorimipramine in endogenous depression","volume":"4","author":"Doogan","year":"1982","journal-title":"J. Affect. Disord."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"419S","DOI":"10.1111\/j.1365-2125.1983.tb02132.x","article-title":"A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine","volume":"15","author":"Dick","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/03007999009111499","article-title":"Fluvoxamine and imipramine in the treatment of depressive patients: A double-blind controlled study","volume":"12","author":"Gonella","year":"1990","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"411S","DOI":"10.1111\/j.1365-2125.1983.tb02131.x","article-title":"A double-blind controlled clinical trial comparing fluvoxamine with imipramine","volume":"15","author":"Guelfi","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1981.tb00756.x","article-title":"Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study","volume":"64","author":"Klok","year":"1981","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_143","first-page":"367","article-title":"The role of neuropharmacologic selectivity in antidepressant action: Fluvoxamine versus desipramine","volume":"51","author":"Nathan","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000118918","article-title":"Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine. A double-blind study in depressed inpatients","volume":"26","author":"Gasperini","year":"1992","journal-title":"Neuropsychobiology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2007-1014496","article-title":"Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression-results of a double-blind study","volume":"23","author":"Kasper","year":"1990","journal-title":"Pharmacopsychiatry"},{"key":"ref_146","unstructured":"Placidi, G.F., Dell, L., Lenzi, A., and Cassano, G.B. (1987). Therapeutic response in subtypes of major depression. New Trends Exp. Clin. Psychiatry, 101\u2013107."},{"key":"ref_147","unstructured":"P\u00f6ldinger, W., and Bures, E. (1984). Fluvoxamine in patients with depressive disorder. Proceedings of the International Symposium on Fluvoxamine, Duphar Medical Publications."},{"key":"ref_148","first-page":"33","article-title":"Therapeutische Ergebnisse mit Fluvoxamin und der Einflu\u00df psychotroper Begleitmedikation auf Wirksamkeit und Vertr\u00e4glichkeit","volume":"2","author":"Wagner","year":"1985","journal-title":"Adv. Pharrnacother."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00004850-198607000-00005","article-title":"Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data","volume":"1","author":"Wakelin","year":"1986","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2007-1014428","article-title":"Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression","volume":"24","author":"Swinkels","year":"1991","journal-title":"Pharmacopsychiatry"},{"key":"ref_151","first-page":"718","article-title":"An Italian multicentre experience with fluvoxamine, a new antidepressant drug, versus imipramine","volume":"43","author":"Bramanti","year":"1988","journal-title":"Curr. Ther. Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/711\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:31:11Z","timestamp":1760031071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":151,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ph18050711"],"URL":"https:\/\/doi.org\/10.3390\/ph18050711","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}